OPG, RANKL, and RANK gene polymorphisms and the bone mineral density response to alendronate therapy in postmenopausal Chinese women with osteoporosis or osteopenia.

Zheng, Hui; Wang, Chun; He, Jin-Wei; Fu, Wen-Zhen; Zhang, Zhen-Lin

Zheng, Hui; Wang, Chun; He, Jin-Wei; Fu, Wen-Zhen; Zhang, Zhen-Lin.

Affiliation

Zheng H; Metabolic Bone Disease and Genetic Research Unit, Department of Osteoporosis and Bone Diseases, Shanghai Key Clinical Center for Metabolic Disease, Shanghai Jiao Tong University Affiliated the Sixth People's Hospital, Shanghai, People's Republic of China.

Pharmacogenet Genomics ; 26(1): 12-9, 2016 Jan.

Article in En | MEDLINE | ID: mdl-26426211

Subject(s)

Alendronate/administration & dosage; Bone Density/drug effects; Bone Diseases, Metabolic/drug therapy; Osteoprotegerin/genetics; RANK Ligand/genetics; Receptor Activator of Nuclear Factor-kappa B/genetics; Alendronate/pharmacology; Bone Diseases, Metabolic/genetics; China; Female; Femur Neck/drug effects; Humans; Lumbar Vertebrae/drug effects; Osteoporosis, Postmenopausal/drug therapy; Osteoporosis, Postmenopausal/genetics; Pelvic Bones/drug effects; Polymorphism, Single Nucleotide/drug effects; Postmenopause/genetics; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bone Diseases, Metabolic / Bone Density / Alendronate / RANK Ligand / Receptor Activator of Nuclear Factor-kappa B / Osteoprotegerin Limits: Female / Humans Country/Region as subject: Asia Language: En Journal: Pharmacogenet Genomics Journal subject: FARMACOLOGIA / GENETICA MEDICA Year: 2016 Type: Article

Fulltext

XML

PubMed Links

Search on Google